-
Findings from a population-based prospective cohort study.
-
Trastuzumab deruxtecan does not necessarily require high levels of HER2 expression.
-
Phase 2 FIGHT trial showed biomarker selection beyond HER2.
Esophageal cancer is associated with malnutrition, and weight loss is associated with reduced survival.